Literature DB >> 25190083

CUX1, a haploinsufficient tumour suppressor gene overexpressed in advanced cancers.

Zubaidah M Ramdzan1, Alain Nepveu2.   

Abstract

CUT-like homeobox 1 (CUX1) is a homeobox gene that is implicated in both tumour suppression and progression. The accumulated evidence supports a model of haploinsufficiency whereby reduced CUX1 expression promotes tumour development. Paradoxically, increased CUX1 expression is associated with tumour progression, and ectopic CUX1 expression in transgenic mice increases tumour burden in several tissues. One CUX1 isoform functions as an ancillary factor in base excision repair and the other CUX1 isoforms act as transcriptional activators or repressors. Several transcriptional targets and cellular functions of CUX1 affect tumorigenesis; however, we have yet to develop a mechanistic framework to reconcile the opposite roles of CUX1 in cancer protection and progression.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25190083     DOI： 10.1038/nrc3805

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  84 in total

1.  The Catalogue of Somatic Mutations in Cancer (COSMIC).

Authors:  S A Forbes; G Bhamra; S Bamford; E Dawson; C Kok; J Clements; A Menzies; J W Teague; P A Futreal; M R Stratton
Journal:  Curr Protoc Hum Genet       Date:  2008-04

2.  Nuclear matrix attachment regions of human papillomavirus type 16 repress or activate the E6 promoter, depending on the physical state of the viral DNA.

Authors:  W Stünkel; Z Huang; S H Tan; M J O'Connor; H U Bernard
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

3.  Lymphoid apoptosis and myeloid hyperplasia in CCAAT displacement protein mutant mice.

Authors:  A M Sinclair; J A Lee; A Goldstein; D Xing; S Liu; R Ju; P W Tucker; E J Neufeld; R H Scheuermann
Journal:  Blood       Date:  2001-12-15       Impact factor: 22.113

4.  CUTL1: a key mediator of TGFbeta-induced tumor invasion.

Authors:  Patrick Michl; Julian Downward
Journal:  Cell Cycle       Date:  2006-01-16       Impact factor: 4.534

5.  A method and server for predicting damaging missense mutations.

Authors:  Ivan A Adzhubei; Steffen Schmidt; Leonid Peshkin; Vasily E Ramensky; Anna Gerasimova; Peer Bork; Alexey S Kondrashov; Shamil R Sunyaev
Journal:  Nat Methods       Date:  2010-04       Impact factor: 28.547

6.  Polycystic kidneys caused by sustained expression of Cux1 isoform p75.

Authors:  Chantal Cadieux; Ryoko Harada; Marilène Paquet; Olivier Côté; Marie Trudel; Alain Nepveu; Maxime Bouchard
Journal:  J Biol Chem       Date:  2008-03-20       Impact factor: 5.157

7.  CCAAT displacement protein as a repressor of the myelomonocytic-specific gp91-phox gene promoter.

Authors:  D G Skalnik; E C Strauss; S H Orkin
Journal:  J Biol Chem       Date:  1991-09-05       Impact factor: 5.157

8.  A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor.

Authors:  Brigitte Goulet; Amos Baruch; Nam-Sung Moon; Madeleine Poirier; Laurent L Sansregret; Ann Erickson; Matthew Bogyo; Alain Nepveu
Journal:  Mol Cell       Date:  2004-04-23       Impact factor: 17.970

9.  Mutation analysis of CDP, TP53, and KRAS in uterine leiomyomas.

Authors:  Maria I Patrikis; Emma J Bryan; Nicola A Thomas; Greg E Rice; Michael A Quinn; Mark S Baker; Ian G Campbell
Journal:  Mol Carcinog       Date:  2003-06       Impact factor: 4.784

10.  Comprehensive molecular characterization of human colon and rectal cancer.

Authors: 
Journal:  Nature       Date:  2012-07-18       Impact factor: 49.962
View more
  36 in total

1.  Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS.

Authors:  Ningfei An; Saira Khan; Molly K Imgruet; Sandeep K Gurbuxani; Stephanie N Konecki; Michael R Burgess; Megan E McNerney
Journal:  Blood       Date:  2018-03-28       Impact factor: 22.113

2.  Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549 cells.

Authors:  Mei-Ling Han; Yi-Fan Zhao; Cai-Hong Tan; Ya-Jie Xiong; Wen-Juan Wang; Feng Wu; Yao Fei; Long Wang; Zhong-Qin Liang
Journal:  Acta Pharmacol Sin       Date:  2016-11-14       Impact factor: 6.150

3.  CUX1 stimulates APE1 enzymatic activity and increases the resistance of glioblastoma cells to the mono-alkylating agent temozolomide.

Authors:  Simran Kaur; Zubaidah M Ramdzan; Marie-Christine Guiot; Li Li; Lam Leduy; Dindial Ramotar; Siham Sabri; Bassam Abdulkarim; Alain Nepveu
Journal:  Neuro Oncol       Date:  2018-03-27       Impact factor: 12.300

4.  The DNA methylation landscape of human melanoma.

Authors:  Seung-Gi Jin; Wenying Xiong; Xiwei Wu; Lu Yang; Gerd P Pfeifer
Journal:  Genomics       Date:  2015-09-15       Impact factor: 5.736

5.  Upregulated Expression of CUX1 Correlates with Poor Prognosis in Glioma Patients: a Bioinformatic Analysis.

Authors:  Xiujie Wu; Fan Feng; Chuanchao Yang; Moxuan Zhang; Yanhao Cheng; Yayun Zhao; Yayu Wang; Fengyuan Che; Jian Zhang; Xueyuan Heng
Journal:  J Mol Neurosci       Date:  2019-08-03       Impact factor: 3.444

6.  CUX2 protein functions as an accessory factor in the repair of oxidative DNA damage.

Authors:  Ranjana Pal; Zubaidah M Ramdzan; Simran Kaur; Philippe M Duquette; Richard Marcotte; Lam Leduy; Sayeh Davoudi; Nathalie Lamarche-Vane; Angelo Iulianella; Alain Nepveu
Journal:  J Biol Chem       Date:  2015-07-28       Impact factor: 5.157

7.  Loss of a 7q gene, CUX1, disrupts epigenetically driven DNA repair and drives therapy-related myeloid neoplasms.

Authors:  Molly K Imgruet; Julian Lutze; Ningfei An; Bonnie Hu; Saira Khan; Jeffrey Kurkewich; Tanner C Martinez; Donald Wolfgeher; Sandeep K Gurbuxani; Stephen J Kron; Megan E McNerney
Journal:  Blood       Date:  2021-09-02       Impact factor: 25.476

8.  Distinct clinical and biological implications of CUX1 in myeloid neoplasms.

Authors:  Mai Aly; Zubaidah M Ramdzan; Yasunobu Nagata; Suresh K Balasubramanian; Naoko Hosono; Hideki Makishima; Valeria Visconte; Teodora Kuzmanovic; Vera Adema; Aziz Nazha; Bartlomiej P Przychodzen; Cassandra M Kerr; Mikkael A Sekeres; Mohamed E Abazeed; Alain Nepveu; Jaroslaw P Maciejewski
Journal:  Blood Adv       Date:  2019-07-23

9.  A genetic signature of the evolution of loss of flight in the Galapagos cormorant.

Authors:  Alejandro Burga; Weiguang Wang; Eyal Ben-David; Paul C Wolf; Andrew M Ramey; Claudio Verdugo; Karen Lyons; Patricia G Parker; Leonid Kruglyak
Journal:  Science       Date:  2017-06-02       Impact factor: 47.728

10.  Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo.

Authors:  Eleni Anastasiadou; Anita G Seto; Xuan Beatty; Melanie Hermreck; Maud-Emmanuelle Gilles; Dina Stroopinsky; Lauren C Pinter-Brown; Linda Pestano; Cinzia Marchese; David Avigan; Pankaj Trivedi; Diana M Escolar; Aimee L Jackson; Frank J Slack
Journal:  Clin Cancer Res       Date:  2020-11-18       Impact factor: 13.801
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.